메뉴 건너뛰기




Volumn 13, Issue 2, 2013, Pages 153-157

Evaluation of crushed ticagrelor tablet doses: Recovery following crushing and naso-gastric tube passage ex vivo

Author keywords

[No Author keywords available]

Indexed keywords

TICAGRELOR; WATER;

EID: 84879733565     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-013-0018-4     Document Type: Article
Times cited : (20)

References (19)
  • 1
    • 84856158305 scopus 로고    scopus 로고
    • ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
    • 21873419 10.1093/eurheartj/ehr236
    • Hamm CW, Bassand J-P, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32:2999-3054.
    • (2011) Eur Heart J , vol.32 , pp. 2999-3054
    • Hamm, C.W.1    Bassand, J.-P.2    Agewall, S.3
  • 2
    • 77649126524 scopus 로고    scopus 로고
    • Heart disease and stroke statistics 2010 update: A report from the American Heart Association
    • 20019324 10.1161/CIRCULATIONAHA.109.192667
    • Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-215.
    • (2010) Circulation , vol.121
    • Lloyd-Jones, D.1    Adams, R.J.2    Brown, T.M.3
  • 3
    • 84865271531 scopus 로고    scopus 로고
    • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines
    • Writing Committee Members 22800849 10.1161/CIR.0b013e318256f1e0
    • Writing Committee Members, Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2012;126:875-910.
    • (2012) Circulation , vol.126 , pp. 875-910
    • Jneid, H.1    Anderson, J.L.2    Wright, R.S.3
  • 4
    • 33744999455 scopus 로고    scopus 로고
    • 12 receptor
    • DOI 10.2174/138161206776361318
    • Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharmaceut Design. 2006;12:1255-9. (Pubitemid 44082134)
    • (2006) Current Pharmaceutical Design , vol.12 , Issue.10 , pp. 1255-1259
    • Storey, R.F.1
  • 5
    • 82255169699 scopus 로고    scopus 로고
    • Evaluating the risk-benefit profile of the direct-acting P2Y12 inhibitor ticagrelor in acute coronary syndromes
    • 22104457 10.3810/pgm.2011.11.2498
    • Husted S. Evaluating the risk-benefit profile of the direct-acting P2Y12 inhibitor ticagrelor in acute coronary syndromes. Postgrad Med. 2011;123:79-90.
    • (2011) Postgrad Med , vol.123 , pp. 79-90
    • Husted, S.1
  • 6
    • 73949112820 scopus 로고    scopus 로고
    • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study
    • 19923168 10.1161/CIRCULATIONAHA.109.912550 1:CAS:528:DC%2BD1MXhsFGgtb3N
    • Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-85.
    • (2009) Circulation , vol.120 , pp. 2577-2585
    • Gurbel, P.A.1    Bliden, K.P.2    Butler, K.3
  • 7
    • 33646261670 scopus 로고    scopus 로고
    • Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin
    • 16476694 10.1093/eurheartj/ehi754 1:CAS:528:DC%2BD28XlsFGqtLs%3D
    • Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-47.
    • (2006) Eur Heart J , vol.27 , pp. 1038-1047
    • Husted, S.1    Emanuelsson, H.2    Heptinstall, S.3
  • 8
    • 35548995394 scopus 로고    scopus 로고
    • Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-st-segment elevation acute coronary syndrome. primary results of the DISPERSE-2 trial
    • DOI 10.1016/j.jacc.2007.07.053, PII S0735109707026344
    • Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-51. (Pubitemid 350007959)
    • (2007) Journal of the American College of Cardiology , vol.50 , Issue.19 , pp. 1844-1851
    • Cannon, C.P.1    Husted, S.2    Harrington, R.A.3    Scirica, B.M.4    Emanuelsson, H.5    Peters, G.6    Storey, R.F.7
  • 9
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • 19717846 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ
    • Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 10
    • 84866732231 scopus 로고    scopus 로고
    • ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)
    • 22922416 10.1093/eurheartj/ehs289 1:CAS:528:DC%2BC38XhsFektbrE
    • Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569-619.
    • (2012) Eur Heart J , vol.33 , pp. 2569-2619
    • Steg, P.G.1    James, S.K.2    Atar, D.3
  • 13
    • 28844484174 scopus 로고    scopus 로고
    • Medication-related swallowing difficulties may be more common than we realise
    • Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Pract. 2005;15:411-4. (Pubitemid 41771408)
    • (2005) Pharmacy in Practice , vol.15 , Issue.10 , pp. 411-414
    • Strachan, I.1    Greener, M.2
  • 15
    • 27644548513 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: Randomised placebo-controlled trial
    • DOI 10.1016/S0140-6736(05)67660-X, PII S014067360567660X
    • Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet. 2005;366:1607-21. (Pubitemid 41552416)
    • (2005) Lancet , vol.366 , Issue.9497 , pp. 1607-1621
    • Chen, Z.1    Jiang, L.2
  • 17
    • 62949141274 scopus 로고    scopus 로고
    • Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    • 19332184 10.1016/j.ahj.2009.01.003 1:CAS:528:DC%2BD1MXjslyisrg%3D
    • James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599-605.
    • (2009) Am Heart J , vol.157 , pp. 599-605
    • James, S.1    Akerblom, A.2    Cannon, C.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.